Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
Author(s)
Alexis, Frank; Molnar, Linda K.; Farokhzad, Omid C.; Pridgen, Eric M.
DownloadAlexis-2008-Factors Affecting the Clearance.pdf (592.4Kb)
PUBLISHER_POLICY
Publisher Policy
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Terms of use
Metadata
Show full item recordAbstract
Nanoparticle (NP) drug delivery systems (5−250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biological barriers and releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating nanoparticles during systemic delivery is a critical issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life. In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation. These factors include interactions with biological barriers and tunable nanoparticle parameters, such as composition, size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization. All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.
Date issued
2008-08Department
MIT-Harvard Center for Cancer Nanotechnology Excellence; Harvard University--MIT Division of Health Sciences and Technology; Massachusetts Institute of Technology. Department of Chemical Engineering; Koch Institute for Integrative Cancer Research at MITJournal
Molecular Pharmaceutics
Publisher
American Chemical Society (ACS)
Citation
Alexis, Frank et al. “Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles.” Molecular Pharmaceutics 5.4 (2008): 505–515. © 2008 American Chemical Society
Version: Final published version
ISSN
1543-8384
1543-8392